Diabetic Macular Edema Retinal Vein Occlusion Wet Age-related Macular Degeneration Subchoroidal Neovascularization Of Macular Choroid
Conditions
Interventions
Test group:Intravitreous injection of anti VEGF drugs
Sponsors
The Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged between 18 and 80 years old, regardless of gender. The patient is diagnosed with DME, AMD, BRVO, CNV; Patients who need to receive intravitreal injection of anti VEGF drugs (ranibizumab, alboxepril, or conbercept) into the affected eye. Injected intraocular pressure ranges from 10mmHg to 21mmHg. Patients who voluntarily sign informed consent forms.
Exclusion criteria
Exclusion criteria: patients with vitreous hemorrhage, Retinal detachment, retinal holes and other diseases that need further surgery. Patients who have or are currently suffering from optic neuropathy, such as glaucoma, optic neuritis, anterior ischemic optic neuropathy, optic atrophy, traumatic optic neuropathy, toxic optic neuropathy, Leber optic neuropathy, etc. Patients who require further panretinal laser photocoagulation treatment after injection. Patients who have received intravitreal injection of anti VEGF drugs or Aodi Shi in the past 3 months; Patients who have received retinal laser photocoagulation therapy, iridectomy laser therapy, and posterior cataract laser therapy within the past 3 months, and patients who have received retrobulbar/parabulbar injection of glucocorticoids within the past 1 month. Patients who have undergone Cataract surgery and glaucoma surgery within 3 months. Patients with severe systemic diseases, such as heart disease, hypertension, abnormal liver and kidney function, abnormal coagulation function, high sensitivity constitution, etc. Mental disorders caused by other causes (physical illness, psychoactive substances). Cognitive impairment caused by severe Alzheimer's disease, Huntington's disease, Hydrocephalus, and long-term use of antiepileptic drugs. Pregnant and lactating women. Patients who cannot cooperate with the examination and patients who cannot communicate normally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity; visual field ;VEP; | — |
Secondary
| Measure | Time frame |
|---|---|
| retrobulbar vascular ultrasound;OCT; | — |
Countries
China
Contacts
Public ContactLiu Fei
The Second Hospital of Dalian Medical University
Outcome results
None listed